Golden Leaf Signs Binding Letter of Agreement to Acquire Leading Oregon Cannabis Business

Canaccord Genuity Toronto to Lead Capital Raise to Fund Acquisition Strategy
TORONTO, ON--( March 22, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH)(OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, is pleased to announce that the Company has signed a binding Letter of Agreement (LOA) to acquire Chalice LLC ("Chalice Farms") (, a leading vertically integrated cannabis company in Oregon (the "Transaction").
In conjunction with the Transaction, the Company has entered into an engagement agreement with Canaccord Genuity Corp. ("Canaccord" or the "Agent") with respect to a best efforts brokered private placement of subscription receipts (the "Subscription Receipts") for anticipated gross proceeds of up to approximately $35 million (the "Offering"). The net proceeds from the Offering are to be used to satisfy the cash component of the purchase price for the Chalice Farms Transaction, as well as to fund the Company's recently announced acquisitions and for existing operations. The Subscription Receipts will be priced in the context of the market.
Read more: Golden Leaf Holdings ( GLH )

Golden Leaf Signs Binding Letter of Intent for Strategic Acquisition in Canada

TORONTO, ON--( March 14, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH)(OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, is pleased to announce that the Company has signed a binding Letter of Intent (LOI) to acquire (the "Transaction") Canadian based Medical Marihuana Group Corporation ("MMGC").
Strategic Fit with GLH
MMGC represents a strategic acquisition for Golden Leaf and provides key benefits to the Company, including:
Access for the GLH brand platform into the rapidly expanding Canadian and international marketplaces;
An international footprint across North America with access to the global marketplace through Canada;
Read more: Golden Leaf Holdings ( GLH )

Tetra Bio-Pharma Enters into Binding Term Sheet for Two Products with Panag Pharma

OTTAWA, ONTARIO--(Marketwired - March 14, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), announced today it has entered into a binding term sheet with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion.
Per the binding term sheet, Tetra will have exclusive access to sell the ocular and topical drug products in North America with right of first negotiation for outside U.S. and Canadian territories. In addition, Tetra will have a right of first negotiation for future products. 
Tetra will be working in close collaboration with Panag's team of experts to ensure a rapid and successful development. Tetra shall be responsible for 100% of the research and development of the Licensed Products. Tetra will own and control all regulatory approvals in the Territory, including the application and any other marketing authorizations within the Territory and shall be responsible for all aspects of commercializing the drug products.
Read more: Tetra Bio-Pharma ( TBP )

Laguna Blends to Acquire 100% Stake in a Global Cannabis Leader with Unaudited Annualized Sales of Approximately $12,000,000 USD 

Vancouver, British Columbia--(March 13, 2017) - Laguna Blends Inc. (CSE: LAG) (OTC Pink: LAGBF) (Frankfurt: LB6A.F) (the "Company" or "Laguna") is pleased to announce that it has signed a letter of Intent (LOI) to acquire 100% interest of a global Cannabis leader with unaudited annualized sales of $12,000,000 USD and adjusted EBITDA of $1,588,000 USD.
This acquisition is a major step forward in establishing Laguna as an international leader in the global cannabis industry. The Target company has an extensive portfolio of intellectual property and hemp driven CBD products including isolates, full spectrum oils, pain creams, oral sprays and other nutraceutical products. The Target company also has a medical division and is currently focusing on Latin America to develop cannabis-based pharmaceutical products.
Read more: Laguna Blends Inc ( LAG )

Aequus Licenses Rights to Cannabinoid Transdermal Patch to Treat Neurological Disorders

VANCOUVER, BC--(March 02, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS)(OTCQB: AQSZF) ("Aequus" or the "Company") announced today that through a previously announced Research Service Contract with Transdermal Research Pharma Lab ("TRPL") it has entered into a binding term sheet (the "Term Sheet") to acquire an exclusive world-wide license to a transdermal patch containing cannabinoids, for the use in epilepsy, Multiple Sclerosis (MS), and certain other neurological disorders.
Aequus has been focused on expanding treatment options for neurological disorders through its current pipeline of development stage and in-licensed products. Aequus recognizes there has been an increased acceptance around the use of cannabinoids for epilepsy and MS in particular, however, uptake by the medical community has been limited by a need for a product that provides precise, controlled dose delivery. The majority of clinical studies performed to date have used orally ingested or inhaled forms of delivery, and further to the challenges with consistency of dosing, these routes of delivery are commonly associated with gastrointestinal side effects such as diarrhea that would be expected to be significantly reduced with a transdermal form.
Read more: Aequus Pharmaceuticals ( AQS )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker